Indonesia and Russia are in talks to collaborate on pharmaceutical technology transfers, aiming to bolster Indonesia’s domestic medicine production and reduce dependency on imports. The discussions involved Indonesia’s Food and Drug Authority (BPOM), led by Taruna Ikrar, and Russian Deputy Minister of Industry and Trade Alexey Vladimirovich Gruzdev, focusing on improving pharmaceutical manufacturing, product safety, and regulatory oversight.
Key areas of potential cooperation include the local production of diabetes treatments such as insulin and glucagon-like peptide-1 (GLP-1) medicines, as well as cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products. Russian companies have shown interest in transferring technology and possibly establishing manufacturing facilities in Indonesia, particularly for insulin and oncology medicines.
The discussions also covered the submission of product registration documents by several Russian pharmaceutical companies to BPOM. Both countries reviewed existing collaborations on Good Manufacturing Practice (GMP) inspections, technical training, and information sharing, with the aim of finalizing a memorandum of understanding to create a framework for deeper collaboration.
Russia proposed exploring mutual recognition of GMP certificates to ease regulatory procedures and enhance market access for pharmaceuticals in both nations, a suggestion that will require further talks to ensure regulatory compatibility. To bolster Indonesia’s inspection capabilities, Russia offered technical training, including the use of virtual reality-based simulations for preparing inspectors.
The discussions extended to digital regulatory systems and supply-chain monitoring, with both countries expressing interest in continuing negotiations and expanding cooperation through future meetings and visits to pharmaceutical manufacturing facilities.